Loading filters...
Publications per Year (692 total)
4
1990
7
·
5
·
7
·
10
·
6
1995
10
·
11
·
8
·
8
·
7
2000
14
·
8
·
14
·
29
·
23
2005
25
·
22
·
24
·
34
·
14
2010
21
·
20
·
20
·
21
·
19
2015
26
·
22
·
19
·
26
·
23
2020
35
·
25
·
31
·
35
·
45
2025
14
·
Loaded
Click to load
50 / 692 papers loaded(scroll for more)
20263 papers
GeneralEarly (I-II)2026
Demographics, clinicopathological features, and survival outcomes of women with endometrial neuroendocrine tumors.
Bou Zerdan M et al. Gynecol Oncol. 2026
MSI-H/dMMRAll Stages2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial Cancer.
Rubinstein MM et al. Clin Cancer Res. 2026
Hormone therapyAll Stages2026
The progesterone paradigm: Molecular prognostication in conservative management of endometrial cancer.
Kailasam A et al. Gynecol Oncol. 2026
202529 papers
GeneralAdvanced/Recurrent2025
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).
Eskander RN et al. Int J Gynecol Cancer. 2025
GeneralAll Stages2025
Body composition as a predictive factor for chemotherapy-induced peripheral neuropathy and dose-limiting toxicity in patients with endometrial cancer undergoing carboplatin and paclitaxel.
Aichi M et al. Int J Gynecol Cancer. 2025
MSI-H/dMMRAdvanced/Recurrent2025
Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer.
Bashi A et al. Gynecol Oncol. 2025
GeneralAll Stages2025
Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors.
House NC et al. Cancer Res. 2025
GeneralAdvanced/Recurrent2025
A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors.
Shin SJ et al. Clin Cancer Res. 2025
Hormone therapyAll Stages2025
Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: Results of a specialized oncofertility program.
Dzyubak O et al. Gynecol Oncol. 2025
MSI-H/dMMREarly (I-II)2025
Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma.
Obermair A et al. Int J Gynecol Cancer. 2025
GeneralAll Stages2025
Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
Tyrakis PA et al. Br J Cancer. 2025
Hormone therapyAll Stages2025
Characteristics of endometrial cancer progressed to extrauterine lesions following fertility preserving medroxyprogesterone acetate therapy for young endometrial cancer patients.
Kitazawa S et al. J Gynecol Oncol. 2025
Hormone therapyAll Stages2025
Fertility-sparing treatment outcomes using immune checkpoint inhibitors in endometrial cancer patients with Lynch syndrome.
Yang X et al. J Gynecol Oncol. 2025
GeneralAdvanced/Recurrent2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.
Eskander RN et al. Int J Gynecol Cancer. 2025
MSI-H/dMMRAll Stages2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses.
Ettorre VM et al. Gynecol Oncol. 2025
MSI-H/dMMRAdvanced/Recurrent2025
Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.
Corr BR et al. Gynecol Oncol. 2025
MSI-H/dMMRAdvanced/Recurrent2025
An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study).
Gallego A et al. Int J Gynecol Cancer. 2025
MSI-H/dMMRAll Stages2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
O'Malley DM et al. Gynecol Oncol. 2025
Hormone therapyEarly (I-II)2025
Comparison of oncologic outcomes between completion hysterectomy and no completion hysterectomy in patients who achieved complete response and completed childbearing after fertility-sparing treatment for early-stage endometrial cancer: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3001).
Lee AJ et al. Gynecol Oncol. 2025
Hormone therapyAll Stages2025
Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women.
Hadizadeh F et al. JAMA Oncol. 2025
MSI-H/dMMRAdvanced/Recurrent2025
Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
Ta QD et al. Gynecol Oncol. 2025
HER2+All Stages2025
HER2 expression in an endometrial cancer cohort.
Hacker KE et al. Gynecol Oncol. 2025
HER2+All Stages2025
HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
Cortés-Salgado A et al. Gynecol Oncol. 2025
GeneralAdvanced/Recurrent2025
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.
Lindemann K et al. Gynecol Oncol. 2025
Hormone therapyAll Stages2025
Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer.
Erickson BK et al. Clin Cancer Res. 2025
Hormone therapyAll Stages2025
Genomic and DNA methylomic factors associated with the efficacy of oral medroxyprogesterone acetate on endometrial neoplastic disease.
Sugiyama Y et al. Gynecol Oncol. 2025
HER2+Advanced/Recurrent2025
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.
van Dijk D et al. J Clin Oncol. 2025
MSI-H/dMMRAdvanced/Recurrent2025
Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.
Zhu Y et al. J Gynecol Oncol. 2025
MSI-H/dMMRAdvanced/Recurrent2025
Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
Coleman RL et al. Gynecol Oncol. 2025
GeneralAdvanced/Recurrent2025
Modified posterior pelvic exenteration combined with ileocecal resection for locally advanced endometrial cancer.
Kato K et al. J Gynecol Oncol. 2025
Hormone therapyAll Stages2025
Outcomes of extended progestin therapy in atypical endometrial hyperplasia patients without an initial response to progestin: a retrospective study from two tertiary centers in Korea and Taiwan.
Choi CH et al. J Gynecol Oncol. 2025
Hormone therapyAll Stages2025
Prevalence of and risk factors for endometrial polyps among asymptomatic postmenopausal women with uterovaginal prolapse.
Weigel GM et al. Am J Obstet Gynecol. 2025
202418 papers
ImmunotherapyAdvanced/Recurrent2024
Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study.
Shang X et al. Int J Gynecol Cancer. 2024
Hormone therapyAll Stages2024
Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials.
Chlebowski RT et al. J Clin Oncol. 2024
Hormone therapyEarly (I-II)2024
A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial).
Sakai K et al. J Gynecol Oncol. 2024
Hormone therapyAll Stages2024
Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion.
Bowen MB et al. Clin Cancer Res. 2024
Hormone therapyAll Stages2024
TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway.
Xue F et al. J Gynecol Oncol. 2024
Hormone therapyAll Stages2024
Predictive value of SUVmax from initial 18F-FDG PET/CT scans for treatment outcomes in endometrial cancer patients undergoing fertility sparing management.
Kang OJ et al. Int J Gynecol Cancer. 2024
MSI-H/dMMRAdvanced/Recurrent2024
Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
Dioun S et al. Gynecol Oncol. 2024
HER2+Advanced/Recurrent2024
Detection of antibody-drug conjugate-induced interstitial lung disease using circulating cell-free DNA.
Grinshpun A et al. ESMO Open. 2024
Hormone therapyAll Stages2024
Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
Kim NK et al. Gynecol Oncol. 2024
Hormone therapyAll Stages2024
TSLP enhances progestin response in endometrial cancer via androgen receptor signal pathway.
Lv M et al. Br J Cancer. 2024
GeneralAdvanced/Recurrent2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
Pignata S et al. Ann Oncol. 2024
GeneralAll Stages2024
Intermittent energy restriction inhibits tumor growth and enhances paclitaxel response in a transgenic mouse model of endometrial cancer.
Zhao Z et al. Gynecol Oncol. 2024
MSI-H/dMMRAdvanced/Recurrent2024
Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.
Huo G et al. J Gynecol Oncol. 2024
Hormone therapyAdvanced/Recurrent2024
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
Yonemori K et al. Gynecol Oncol. 2024
MSI-H/dMMRAdvanced/Recurrent2024
Real-world use of immune checkpoint inhibitors in advanced or recurrent endometrial cancer.
Huepenbecker S et al. Int J Gynecol Cancer. 2024
Hormone therapyAll Stages2024
The Intrauterine Device: How to Deploy This Strategy in the Molecular World?
Johannet P et al. Clin Cancer Res. 2024
MSI-H/dMMRAll Stages2024
Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers.
Ozawa R et al. J Gynecol Oncol. 2024
Hormone therapyEarly (I-II)2024
Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
Jang EB et al. Gynecol Oncol. 2024